(Q90916316)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30614472%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

title

Exploring and comparing adverse events between PARP inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30614472%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

3

Anil K Sood

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30614472%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

author name string

Christopher J LaFargue

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30614472%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Graziela Z Dal Molin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30614472%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

Robert L Coleman

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30614472%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

publication date

1 January 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30614472%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

17 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30614472%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30614472%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30614472%20AND%20SRC:MED&resulttype=core&format=json

17 April 2020

page(s)

e15-e28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30614472%20AND%20SRC:MED&resulttype=core&format=json

Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy

17 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Homologous recombination and its regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Regulation and mechanisms of mammalian double-strand break repair

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Mechanism of homologous recombination: mediators and helicases take on regulatory functions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Role of poly(ADP-ribose) formation in DNA repair

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

PARP1- and CTCF-Mediated Interactions between Active and Repressed Chromatin at the Lamina Promote Oscillating Transcription.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in the absence of DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Safety and dose modification for patients receiving niraparib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Management of the toxicities of common targeted therapeutics for gynecologic cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

1 reference

7 January 2021

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

PARP-1 activation causes neuronal death in the hippocampal CA1 region by increasing the expression of Ca(2+)-permeable AMPA receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Poly(ADP-ribose) polymerase inhibition with HYDAMTIQ reduces allergen-induced asthma-like reaction, bronchial hyper-reactivity and airway remodelling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Drug induced interstitial lung disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

iNOS induction and PARP-1 activation in human atherosclerotic lesions: an immunohistochemical and ultrastructural approach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Inhibition of PARP prevents angiotensin II-induced aortic fibrosis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021

Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930786-1

7 January 2021